Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.

General Dentistry

Volumn 58, Issue 6, 2010, Pages 484-492

  Skrepnek, Grant H ^a   Seal, Brian ^b   Tangirala, Muralikrishna ^c,d   Jeffcoat, Marjorie K ^e   Watts, Nelson B ^f   Hay, Joel W ^g  

^a UNIVERSITY OF ARIZONA   (United States)

^b BAYER CORPORATION   (United States)

^c SANOFI   (France)

^d Smith Hanley Consulting Group LLC   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CINCINNATI   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CORTICOSTEROID; ETIDRONIC ACID; IMIDAZOLE DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

AGED; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DATA BASE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; LUNG TUMOR; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM; ORAL DRUG ADMINISTRATION; ORAL SURGERY; OSTEITIS; OSTEOMYELITIS; OSTEOPOROSIS; PREVALENCE; PROSTATE TUMOR; RISK FACTOR; STATISTICS; UNITED STATES;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DATABASES AS TOPIC; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; JAW DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS; ORAL SURGICAL PROCEDURES; OSTEITIS; OSTEOMYELITIS; OSTEOPOROSIS; PREVALENCE; PROSTATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 78650126205     PISSN: 03636771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Reszka AA, Rodan GA. Bisphosphonate mecha nism of action. Curr Rheumatol Rep 2003;5(1): 65-74.
2. Weinstein RS, Roberson PK, ManolagasSC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009; 360(1):53-62,
3. Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of action and role in clinical prac tice. Mayo Ctin Proc 2008;83(9):1032-1045.
4. ODS postmarketing safety review. Available at: www.fda.gov/ohrms/dockets/ ac/05/briefing/ 2005-4095B2 03 04-FDA-TAB3.pdf. Accessed July 2010.
5. Early communication of an ongoing safety re view on bisphosphonates: Alendroriate (Fosa- max, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel W/Caldum), tiludronate (Skelid), and zoledronic acid (Redast, Zometa). Available at: http://www.fda gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/DrugSafety InformationforHeathcareProfessionals/ ucm070303.htm. Accessed July 2010.
6. Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Redast, Skelid, and Zometa) infor mation. Available at: http://www.fda.gov/Drugs/ DrugSafety/ PostmarketDrugSafetylnformation- forPatierttsa ndProviders/ucm 101551. htm. Ac cessed July 2010.
7. Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA; American Denial Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteone- crosisoftheJaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008; 139(12):1674-1677.
8. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofadal Surgeons. Task Force on Bisphosphonate-Related Osteonecrosis of the Jaw, American Assodation of Oral and Maxil- lofacial Surgeons position paper on bisphospho- nate-related osteonecrasis of the jaw-2009 update. Available at: http://www.aaoms.orcj/ docs/position-papers/b ronj-update.pdf. Ac cessed July 2010,
9. Khosla S, BurrD, CauleyJ, Dempster DW, Ebel- ing PR, Eelsenberg D, Gagel RF, GilsanzV, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH,Watts N,Woo SB, Shane E; Ameri can Society for Bone and Mineral Research. Bisphosphonate-assodated osteonecrasis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007,22(10):1479-1491.
10. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully C. Avascular jaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases.) Oral Pathol Med2005;34(2):120-123,
11. Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC Jr. Bisphosphonates and jaw osteo- necrosis: The UAMS experience. Otolaryngol Head Neck Surg 2007;136(3):396-400.
12. Lugassy G, Shaham R, Memets A, Ben-Dor D, Nahlieli 0. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: A new clinical entity. Am J Med 2004; 117(6):440-441.
13. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg2003;61(9):1115- 1117.
14. Marx RE, Sawatari V, Fortin M, Broumand V, Bisphosphonate-induced exposed bone (osteo- necrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567-1575.
15. Migliorati CA, Schubert MM, Peterson DE, Sene- da LM. Bisphosphonate-assodated osteonecro- sis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 2005;104(1):83-93.
16. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB, Managing the care of pa tients with bisphosphonate-associated osteone- crosis: An Academy of Oral Medicine position paper. J Am Dent Assoc2005;136(12):1658- 1668.
17. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007, 86(11):1013-1021.
18. Ruggiero S, GralowJ, Marx RE, HoffAO, Schubert MM, Huryn JM, Totfi B, Damato K, Valero V, Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer, J Oncol Pract 2006;
19. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527-34.
20. Zavras AI, Zhu S. Bisphosphonates are associat ed with increased risk for jaw surgery in medical claims data: Is it osteonecrosis? J Oral Maxillo- facSurg2006;64(6):917-923.
21. Charlson ME, Pompei P,Ales KL, McKenzie CR.A new method of classifying prognostic comorbid- ity in longitudinal studies: Development and validation. J Chronic Dis 1987;40(5):373-383.
22. DeyoRA, CherkinDC, Ciol MA. Adapting a clini- cal comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45(6):613-619.
23. Dehejia RH, Wahba S. Propensity score-match ing methodsfor non-experimental causal stud ies. Rev Econ Stat 2002;84:151.
24. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 2006;9(6):377- 385,
25. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: A medical claims study of 714,217 people. J Am DentAssoc2008;139(1):23-30.
26. Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 2008;121(6):475-483,e3,
27. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Associa tion of Oral and Maxillofadal Surgeons, Ameri can Association of Oral and Maxillofadal Surgeons position paper on bisphospbonate-re-lated osteonecrosis of the jaw. J Oral Maxillofac Surg 2007;65(3):369-376.
28. Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angril- li F, Pennese E, Quarta G, Stelitano C, Caparotti G, Luminari S, Musto P, Natale D, Broglia C, Cuogtii A, Dini D, Di Tonno P, Leonardi G, Piane- zze G, PitiniVPolimeno G, Ponchio L, Hasini L, Musso M, Spriano M, Pollastri G; Gruppo Italia- no Studio Linfomi. Bisphosphonate-assodated osteonecrosis of the jaw: A review of 35 cases and an evaluation of its frequency in multiple myeloma. Leuk Lymphoma 2007;48(1):56-64.
29. BamiasA, KastritisE, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, AnagnostopoulosA, PapadimitriouC, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005, 23(34):8580-8587.
30. BoonyapakornT, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteo necrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other ma lignancies. Oral Oncol 2008;44(9):857-69,
31. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, MoulopDulos LA, Bamia CJerpos EJsionos K, BamiasA.Osteo necrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evi dence of increased risk after treatment with zoledronic add. Haematologica 2006;91(7): 968-971
32. HoffAO,TothBB,Altundag K, Johnson MM, Wameke CL, Hu M, Nooka A, Sayegh G, Guar- neri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in can cer patients treated with intravenous bisphos phonates. J Bone Miner Res 2008;23(6): 826-836,
33. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353(1):99-102.
34. Wang EP, Kaban LB, Strewler GJ, Raje NJroutis MJ. Incidence of osteonecrosis of the jaw in pa tients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral and Maxillo Surg 2007,65(7): 1328-1331.
35. Pazianas M, Miller P, BlumentalsWA, Bernal M, Kothawala P. A review of the literature on os teonecrosis of the jaw in patients with osteopo rosis treated with oral bisphosphonates: Prevalence, risk factors, and clinical characteris tics. Clin Ther2007;29(8): 1548-58.
36. Coding FAQ. Available at: http:Wwww.aaoms. org/faq-coding.php#25. Accessed July 2010.
37. WessellJH,DodsonTB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillo Surg2008;66(4):625-631.